HRMY (STOCKS)
Harmony Biosciences Holdings, Inc. Common Stock
$35.850000
-0.740000 (-2.02%)
Prev close: $36.590000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jeffrey M. Dayno
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,064.25M
- Employees
- 268
- P/E (TTM)
- 11.52
- P/B (TTM)
- 2.52
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
11
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$0.87 | $0.86 | +0.0139 | +1.62% |
|
Jun 2025 (Q2)
|
$0.68 | $0.77 | -0.0855 | -11.17% |
|
Mar 2025 (Q1)
|
$0.78 | $0.60 | +0.1846 | +31.00% |
|
Dec 2024 (Q4)
|
$0.85 | $0.75 | +0.0965 | +12.81% |
Financial Statements
| Revenues | $825.94M |
| Benefits Costs and Expenses | $595.49M |
| Cost Of Revenue | $184.21M |
| Costs And Expenses | $595.49M |
| Gross Profit | $641.74M |
| Operating Expenses | $416.10M |
| Research and Development | $174.33M |
| Other Operating Expenses | $241.77M |
| Operating Income/Loss | $225.64M |
| Income/Loss From Continuing Operations After Tax | $185.68M |
| Income/Loss From Continuing Operations Before Tax | $230.46M |
| Income Tax Expense/Benefit | $44.78M |
| Net Income/Loss | $185.68M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $185.68M |
| Net Income/Loss Available To Common Stockholders, Basic | $185.68M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $3.23 |
| Diluted Earnings Per Share | $3.18 |
| Basic Average Shares | 172,400,903 |
| Diluted Average Shares | 175,785,509 |
| Assets | $1.21B |
| Current Assets | $838.80M |
| Inventory | $6.88M |
| Prepaid Expenses | $23.31M |
| Other Current Assets | $808.61M |
| Noncurrent Assets | $369.42M |
| Fixed Assets | $1.44M |
| Intangible Assets | $95.38M |
| Other Non-current Assets | $272.60M |
| Liabilities | $373.10M |
| Current Liabilities | $223.40M |
| Accounts Payable | $26.34M |
| Wages | $14.94M |
| Other Current Liabilities | $182.13M |
| Noncurrent Liabilities | $149.69M |
| Long-term Debt | $168.51M |
| Equity | $835.12M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $835.12M |
| Liabilities And Equity | $1.21B |
| Net Cash Flow From Operating Activities | $297.61M |
| Net Cash Flow From Operating Activities, Continuing | $297.61M |
| Net Cash Flow From Investing Activities | -$29.20M |
| Net Cash Flow From Investing Activities, Continuing | -$29.20M |
| Net Cash Flow From Financing Activities | -$8.78M |
| Net Cash Flow From Financing Activities, Continuing | -$8.78M |
| Net Cash Flow | $259.63M |
| Net Cash Flow, Continuing | $259.63M |
| Comprehensive Income/Loss | $185.53M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $185.53M |
| Other Comprehensive Income/Loss | $90.50M |